ClinicalTrials.gg
Not yet recruitingNCT07529665Updated Apr 14, 2026

Efficacy of Immersive Virtual Reality Combined With Stationary Cycling on Gait in Individuals With Stroke

An interventional study of Neurological Physiotherapy intervention (NP). and Virtual Reality Combined with Stationary Cycling intervention (VR-SC) in Stroke, sponsored by University of Cadiz. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by University of Cadiz · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate whether an intervention based on immersive virtual reality combined with stationary cycling, in addition to neurological physiotherapy, improves gait in individuals with stroke. The study will also assess the effects of this intervention on balance, coordination, motor function, muscle tone, and participants' and therapists' satisfaction.

The main questions this study aims to answer are:

  • Does immersive virtual reality combined with stationary cycling improve gait compared with neurological physiotherapy alone?
  • Does this combined intervention improve balance, coordination, motor function, and muscle tone in individuals with stroke?
  • How do participants and therapists perceive the use of immersive virtual reality combined with stationary cycling during rehabilitation?

Researchers will compare a program that combines immersive virtual reality and stationary cycling with neurological physiotherapy to a neurological physiotherapy program alone.

Participants will:

  • Take part in two intervention periods, with a total of 16 sessions over 8 weeks (two sessions per week).
  • Receive intervention sessions that include immersive virtual reality combined with stationary cycling and neurological physiotherapy, or neurological physiotherapy alone, depending on the intervention period.
  • Complete assessments of gait, balance, and motor function at baseline, after the first intervention period, and after the second intervention period.
02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • virtual reality
  • stationary cycling
03

In context

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

This study's planned enrollment of 25 is below the median of 48 across 6,049 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Cadiz is the lead sponsor of 55 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older with a medically documented diagnosis of hemorrhagic or ischemic stroke.
  • At least 6 months post-stroke.
  • Presence of hemiparesis.
  • Mild to moderate balance impairment, defined as a Berg Balance Scale score \< 50.
  • Gait impairment, defined as a Wisconsin Gait Scale score > 20.
  • Preserved active movement in the lower limbs and ability to mount and remain seated on the stationary bicycle.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac conditions.
  • Visual or auditory impairments limiting the use of virtual reality head-mounted displays.
  • Medical history of epilepsy.
  • Severe attentional impairment or inability to cooperate with the study intervention.
  • Severe cognitive impairment and marked difficulties in comprehension.
  • Severe vestibular disorders and predisposition to dizziness or vomiting.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Neurological Physiotherapy (Group A)

    The neurological physiotherapy group will receive in 16 therapy sessions over 8 weeks, with two sessions per week. The study includes two treatment periods, each lasting 4 weeks and including 8 sessions. There will be a 4-week break between the two treatment periods, during which no study treatment will be provided.

    Other: Neurological Physiotherapy intervention (NP). · Device: Virtual Reality Combined with Stationary Cycling intervention (VR-SC)

  • Experimental
    Virtual Reality Combined with Stationary Cycling (Group B)

    Virtual Reality Combined with Stationary Cycling group will receive in 16 therapy sessions over 8 weeks, with two sessions per week. The study includes two treatment periods, each lasting 4 weeks and including 8 sessions. There will be a 4-week break between the two treatment periods, during which no study treatment will be provided.

    Other: Neurological Physiotherapy intervention (NP). · Device: Virtual Reality Combined with Stationary Cycling intervention (VR-SC)

Interventions

  • OtherNeurological Physiotherapy intervention (NP).

    The Neurological Physiotherapy intervention (NP) will include 60-minute sessions structured into six therapeutic blocks: gait training; trunk control; balance, righting and stepping reactions; lower limb strengthening; stretching of the affected lower limb; and sensory stimulation of the affected foot. Each block will last approximately 5 to 15 minutes per session, depending on the individual needs of the participant.

  • DeviceVirtual Reality Combined with Stationary Cycling intervention (VR-SC)

    The Virtual Reality Combined with Stationary Cycling intervention (VR-SC) will include 15 to 30 minutes of immersive virtual reality using the HOLOFIT VR Fitness software combined with stationary cycling, in addition to 30 minutes of neurological physiotherapy intervention (NP). Due to the reduced time allocated to NP, each therapeutic block will last approximately 2 to 10 minutes per session, depending on the individual needs of the participant. The VR-SC intervention will be delivered in five phases with progressively increasing cycling intensity and will include three virtual reality game modes (Exploration, Cardiogoals, and Race). Exercise intensity will vary across phases based on heart rate (HR), measured using a pulse oximeter. Stationary cycling resistance will be adjusted to keep the participant's HR within a predefined percentage range of maximum heart rate (HRmax).

06

What researchers measure

Primary outcomes

  1. Qualitative Gait Assessment

    The outcome measures will include the Wisconsin Gait Scale (WGS) for qualitative gait assessment. The Wisconsin Gait Scale consists of 14 observable items that analyze gait components. Each item is scored from 1 (normal) to 3 (atypical), except for item 1 (scored from 1 to 5) and item 11 (scored from 1 to 4). Total scores range from 13.35 to 42, with higher scores indicating greater gait impairment.

    Time frame: The research team will conduct assessments at baseline, after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

  2. Quantitative Gait Assessment

    The outcome measures will include the 6-Minute Walk Test (6MWT) for quantitative gait assessment. The 6-Minute Walk Test measures the total distance in meters that the participant can walk within six minutes. The test is performed on a 30-meter course marked by two cones, with a chair available for rest if needed.

    Time frame: The research team will conduct assessments at baseline, after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

Secondary outcomes

  1. Balance

    The outcome measures will include the Berg Balance Scale (BBS). Scores range from 0 to 56, with lower scores indicating greater balance impairment.

    Time frame: The research team will conduct assessments at baseline, after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

  2. Motor Function

    The outcome measures will include the Fulg-Meyer Lower Extremity (FM). This scale includes five domains. In this study, the motor function and coordination/speed domains of the lower extremity will be evaluated. Scores range from 0 to 34 points for the selected domains, with lower scores indicating greater motor function and coordination impairment.

    Time frame: The research team will conduct assessments at baseline, after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

  3. Spasticity

    The outcome measures will include the Modified Ashworth Scale (MAS). The Modified Ashworth Scale measures resistance to passive muscle stretching on a 0 to 4 scale, where 0 indicates no increase in muscle tone and 4 indicates higher spasticity in flexion or extension. Spasticity assessment will focus on the hip adductors, hamstrings and triceps surae of the lower limb, as well as the pectoralis major, biceps brachii, and finger flexors of the upper limb.

    Time frame: The research team will conduct assessments at baseline, after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

Other outcomes

  1. Perceived improvement

    The outcome measures will include the Patient Global Impressions of Improvement (PGI-I). A single-item measure, from 0 to 7, in which participants rate their perceived change in condition following the intervention. Higher scores indicating perceived improvement because of the therapy.

    Time frame: The research team will assess participant perception after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

  2. User experience satisfaction in virtual reality

    To assess satisfaction with VR as a therapeutic tool, both participants and clinicians will rate their satisfaction with the intervention program and technological devices on a 0-10 numeric scale, where 0 indicates very low satisfaction and 10 indicates complete satisfaction.

    Time frame: The research team will assess participant perception after the first intervention period (4 weeks after baseline), and after the second intervention period (12 weeks after baseline).

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jan 2027, 8 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 8 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 14, 2026
StartEst.
May 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07529665
Lead sponsor
University of Cadiz
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 14, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion